Pfizer, Inc.
New York, NY, United States
Company overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
InvestorStack coverage
Latest articles
Market News
Pfizer's 6.9% Dividend Yield Stands Out as Shares Sit Near Multi-Year Lows
Pfizer shares are down over 50% from 2021 highs, pushing its dividend yield to 6.9% — far above the S&P 500's 1.1% and the pharma sector average of 1.5%.
Market News
Pfizer's Monthly GLP-1 Drug Berobenatide Could Shake Up the Weight-Loss Market Dominated by Lilly and Novo Nordisk
Pfizer's once-monthly GLP-1 candidate Berobenatide shows promising phase three data, potentially offering a dosing advantage over Lilly and Novo Nordisk's weekly injections.
Market News
Pfizer Shares Slide 2.74% as CFO Dave Denton's August Departure Raises 2026 Guidance Concerns
Pfizer fell 2.74% to $25.21 on June 18 after announcing CFO Dave Denton's August departure, with trading volume running 85% above average amid 2026 guidance concerns.
Market News
Three High-Yield Healthcare Dividend Stocks Drawing Retiree Interest in 2026
Analysts highlight Pfizer, Medtronic, and Omega Healthcare as income-generating healthcare investments offering yields from 3.6% to 6.5% for retirement portfolios.